Literature DB >> 22285996

Ruxolitinib for myelofibrosis therapy: current context, pros and cons.

A Pardanani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22285996     DOI： 10.1038/leu.2012.21

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors:  G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

2.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

3.  Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling.

Authors:  Danny Hung-Chieh Chou; Amedeo Vetere; Amit Choudhary; Stephen S Scully; Monica Schenone; Alicia Tang; Rachel Gomez; Sean M Burns; Morten Lundh; Tamara Vital; Eamon Comer; Patrick W Faloon; Vlado Dančík; Christie Ciarlo; Joshiawa Paulk; Mingji Dai; Clark Reddy; Hanshi Sun; Matthew Young; Nicholas Donato; Jacob Jaffe; Paul A Clemons; Michelle Palmer; Steven A Carr; Stuart L Schreiber; Bridget K Wagner
Journal:  J Am Chem Soc       Date:  2015-06-15       Impact factor: 15.419

4.  Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.

Authors:  Michaela Waibel; Vanessa S Solomon; Deborah A Knight; Rachael A Ralli; Sang-Kyu Kim; Kellie-Marie Banks; Eva Vidacs; Clemence Virely; Keith C S Sia; Lauryn S Bracken; Racquel Collins-Underwood; Christina Drenberg; Laura B Ramsey; Sara C Meyer; Megumi Takiguchi; Ross A Dickins; Ross Levine; Jacques Ghysdael; Mark A Dawson; Richard B Lock; Charles G Mullighan; Ricky W Johnstone
Journal:  Cell Rep       Date:  2013-11-21       Impact factor: 9.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.